Money

Gilead Sciences Inc. Bolsters Growth Prospects with Strategic Acquisitions and Pipeline Innovations

authorBy T. Harv Eker

DateMar 15, 2026

Read time2 min

Gilead Sciences Inc., a prominent biopharmaceutical firm, is exhibiting strong growth indicators, underscored by recent analyst endorsements. Jefferies initiated coverage with a 'Buy' rating and a $180 price target, highlighting the company's potential for increased earnings per share and expanding profit margins. This positive outlook is largely attributed to Gilead's robust HIV drug portfolio and the anticipated success of upcoming products.

The company is making significant advancements in its product development pipeline and strategic collaborations. A key development is the successful completion of the Phase 3 RAINIER trial for povetacicept, which met its primary and secondary goals in treating immunoglobulin A nephropathy (IgAN). Furthermore, Gilead's commitment to expanding its therapeutic reach is evident in its substantial $7.8 billion agreement to acquire Arcellx, a blood cancer drug developer. This acquisition builds on a long-standing partnership focused on commercializing treatments for multiple myeloma, reinforcing Gilead’s strategic focus on oncology.

Gilead Sciences, a U.S.-based biopharmaceutical innovator, is dedicated to discovering, developing, and marketing groundbreaking medications for severe illnesses, particularly in the fields of virology, oncology, and inflammatory conditions. Renowned for its pioneering work in antiviral therapies for HIV, Hepatitis B and C, and COVID-19, the company is actively broadening its global footprint, with a particular emphasis on the Asian market. This proactive approach ensures Gilead remains at the forefront of medical innovation, consistently delivering solutions that improve patient outcomes worldwide.

Gilead's proactive strategies in drug development and market expansion illustrate a company dedicated to improving global health. By investing in promising therapies and forging strategic alliances, Gilead not only strengthens its market position but also contributes significantly to medical progress, offering hope and advanced treatment options to patients battling life-threatening diseases.

Micron Technology's Earnings Focus: AI Demand and Memory Pricing Power

Micron Technology is set to announce its fiscal second-quarter 2026 earnings on March 18, with analysts projecting significant revenue and earnings growth driven by surging artificial intelligence (AI) memory demand. The key factor for investors to monitor is the persistence of the memory supply-demand imbalance beyond 2026, which is crucial for Micron's sustained pricing power and profitability in the highly cyclical semiconductor industry.

By Ramit SethiMar 15, 2026

Piper Sandler Maintains Neutral Rating on e.l.f. Beauty Following February Data Adjustments

Piper Sandler has reaffirmed its Neutral stance on e.l.f. Beauty (ELF) after revised February sales data indicated a slight moderation in product consumption growth to 6%. Despite this, the company's Q4 year-to-date performance remains robust at approximately 7%, aligning with Q3 results. The broader U.S. mass cosmetics market exhibited stable, single-digit growth. e.l.f. Beauty also reported strong Q3 fiscal 2026 financial results, with net sales surging by 38%, driven by market share gains and channel expansion.

By Ramit SethiMar 15, 2026

UBS Cuts Berkshire Hathaway Target Amidst Quarterly Setbacks

UBS has lowered its price target for Berkshire Hathaway's Class A shares to $866,429 from $880,905, while maintaining a Buy rating. This adjustment follows weaker-than-expected quarterly results and a cautious outlook for the reinsurance sector. Despite these challenges, the firm anticipates Berkshire Hathaway's stock to perform well in uncertain geopolitical environments, citing its diverse earnings, strong liquidity, and U.S.-centric operations. UBS also foresees management prioritizing margin improvements at BNSF, enhancing GEICO's retention, and upholding disciplined pricing in reinsurance for 2026–2027.

By Scott PapeMar 15, 2026

Barclays Upgrades Willis Towers Watson Amidst AI-Driven Industry Shifts

Barclays has elevated its rating for Willis Towers Watson Public Limited Company (WTW) to 'Equal Weight,' increasing its price target to $341 from $318. This adjustment reflects the firm's belief that concerns over AI's impact on the insurance brokerage sector are overstated. Barclays highlights WTW's robust specialist approach and the potential for AI to enhance efficiency and profitability, advocating for the underlying strength of the brokerage model.

By Natalie PaceMar 15, 2026

BofA Raises Eni S.p.A. Price Target, Citing Increased Oil and Gas Forecasts

Bank of America (BofA) has increased its price target for Eni S.p.A. (E) from EUR 18.50 to EUR 21, maintaining a Neutral rating. This adjustment reflects BofA's revised oil and gas price forecasts for 2026-27, driven by potential disruptions in the Strait of Hormuz. Eni recently reported robust Q4 2025 results, with a 35% year-over-year increase in adjusted net income and strong cash flow, alongside strategic operational agreements.

By Scott PapeMar 15, 2026